Angiolutions
Angiolutions is a German medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant that halts early-stage abdominal aortic aneurysm progression by absorbing aortic pulse waves. It targets vascular surgeons and hospitals serving AAA patients, and is currently in first-in-human clinical trials.
- Company typePrivate
- Founded2020
- HeadquartersDe Pere, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Angiolutions does
Angiolutions GmbH is a privately held medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant designed to halt the progression of early-stage abdominal aortic aneurysms (AAAs). The device acts as a mechanical shield that locally modulates and absorbs aortic pulse waves driving aneurysm growth, addressing the root cause of disease progression rather than the symptoms, and offering an active therapeutic option for the roughly 5% of the population affected by AAAs who currently face a 'watch and wait' surveillance paradigm with no approved intervention. The technology is protected by 16 filed patents across 5 patent families, with grants in both the US and EU, and is supported by an ISO 13485-certified quality management system.
The company is conducting the PRINCIPIIS-FIH first-in-human clinical trial, with the first patient treated in December 2025 at centers in Tashkent, Uzbekistan; additional trial sites include University Hospital Düsseldorf, Marienhospital Gelsenkirchen, and University Hospital Leipzig. The product consists of the A3-Shield® implant and its dedicated delivery system. The company is led by physician-founders and Co-CEOs Dr. Isabel N. Schellinger and Dr. Uwe Raaz, with Chief Business Officer Marius Rummel, supported by an interdisciplinary team and an Advisory Board and Medical Board of international vascular surgery and MedTech industry veterans.
Angiolutions is pre-revenue, with the A3-Shield® System classified as an investigational device not yet approved for commercial sale. Its business model is structured around future one-time device sales to hospitals and vascular surgery centers across the EU and US, pursued via direct enterprise field sales once regulatory approval is obtained. To date the company has been capitalized by a €2.5 million non-dilutive EIC Accelerator grant awarded in July 2023, with no institutional equity investors disclosed; the company is registered in Hannover, Germany.
Angiolutions firmographics
Firmographics- Name
- Angiolutions
- Legal name
- Angiolutions® GmbH
- Website
- https://angiolutions.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Angiolutions is a German medical device company developing the A3-Shield® System, a first-in-class minimally invasive implant that halts early-stage abdominal aortic aneurysm progression by absorbing aortic pulse waves. It targets vascular surgeons and hospitals serving AAA patients, and is currently in first-in-human clinical trials.
- Ownership category
- akta.pro rank
Angiolutions industry classification
Industry- Product category
- Vascular Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where Angiolutions is headquartered
LocationHeadquarters
- HQ city
- De Pere
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Angiolutions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: Pre-revenue company. The A3-Shield® System is an investigational device currently in first-in-human clinical trials and not yet approved for commercial sale. Future revenue will come from direct sales of the implant to hospitals and vascular surgery centers.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Angiolutions product offering
Product offeringCore offering
Angiolutions develops the A3-Shield® System, a first-in-class, minimally invasive implant designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The investigational device consists of the implant and its delivery system and addresses the root cause of AAA progression, an area with no active treatment options currently available. The product is currently in first-in-human clinical trials (PRINCIPIIS-FIH) and not yet approved for commercial sale.
Product overview
Angiolutions offers a single core product: the A3-Shield® System, which consists of the implant and its delivery system. This first-in-class medical device is designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves, addressing the root cause of aneurysm progression. The A3-Shield® System is currently an investigational device undergoing first-in-human clinical testing (PRINCIPIIS-FIH Trial) and is not approved for commercial sale.
Differentiator
Problem solved
Functional benefit
Products and services
- A3-Shield® System First-of-its-kind medical implant system designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The system consists of the A3-Shield® implant and its minimally invasive delivery system, targeting the root cause of AAA progression. Intended for use by vascular surgeons and interventional cardiologists at hospitals and vascular surgery centers treating AAA patients.
Quantifiable outcome
- First patient successfully treated in December 2025 in PRINCIPIIS-FIH first-in-human clinical trial
Companies that use Angiolutions
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Angiolutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Angiolutions partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- DQS (German Society for Certification of Management Systems for Medical Devices)coreDQS conducted the ISO 13485 certification audit for Angiolutions' fully digital quality management system. The audit was conducted thoroughly and efficiently, achieving certification within an ambitious schedule.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Angiolutions competitors and assessment
Company assessmentDirect peers
- Endologix: Pure-play AAA device company with the AFX and Alto endovascular stent graft systems for AAA repair. Most directly comparable as a device-only company focused exclusively on abdominal aortic aneurysm treatment.
- MicroPort Scientific (Lombard Medical): Acquired Lombard Medical, a pure-play AAA stent graft developer (Altura and iCAST). Comparable as a focused AAA device company whose customer base and clinical workflow overlap directly with Angiolutions' target users.
Broad incumbents
- Medtronic: Major vascular MedTech incumbent with the Endurant AAA stent graft system. Operates broadly across vascular intervention but competes directly in the AAA treatment category where Angiolutions aims to introduce earlier-stage intervention.
- Cook Medical: Established AAA player with the Zenith Flex and Zenith Alpha endovascular graft lines. Large diversified medical device company with overlapping vascular surgery customer base and procedural workflows.
- W. L. Gore & Associates: Developer of the Gore Excluder AAA stent graft and other vascular implants. Comparable as a long-standing AAA device innovator with deep vascular surgeon relationships and broad IP in endovascular devices.
- Terumo Aortic: Specialty division of Terumo focused on aortic stent grafts and surgical grafts (formerly Vascutek). Directly comparable in serving vascular surgeons treating aortic disease, including AAA.
- Artivion: Cardiovascular and vascular surgery company (formerly CryoLife) with aortic stent graft and surgical graft portfolio. Comparable as a vascular-focused incumbent serving similar vascular surgeon customers.
- Abbott Vascular: Major vascular device division within Abbott with broad portfolio across coronary and peripheral intervention. Comparable as a scaled incumbent with overlapping interventional cardiology and vascular surgery customers and R&D capabilities.
Emerging players
- Penumbra: Vascular thrombectomy and embolization device company with growing presence in vascular surgery suites. Comparable as an innovative vascular MedTech expanding into new procedural indications served by similar clinicians.
- Shockwave Medical: Developer of intravascular lithotripsy (IVL) for calcified vascular disease. Comparable as a fast-growing vascular device innovator that introduced a novel mechanism of action into established vascular treatment categories.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Angiolutions social profiles
Digital presenceAngiolutions compliance and trust
Trust signalCompliance1 record
Angiolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Angiolutions leadership team
Management profileNumber of profiles
Profiles6 records
Angiolutions funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Angiolutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Angiolutions
What does Angiolutions do?
Angiolutions develops the A3-Shield® System, a first-in-class, minimally invasive implant designed to treat early-stage abdominal aortic aneurysms (AAAs) by locally modulating aortic pulse waves to halt aneurysm growth. The investigational device consists of the implant and its delivery system and addresses the root cause of AAA progression, an area with no active treatment options currently available. The product is currently in first-in-human clinical trials (PRINCIPIIS-FIH) and not yet approved for commercial sale.
Is Angiolutions a public or private company?
Angiolutions is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Angiolutions founded?
Angiolutions was founded in 2020. It employs 1 to 10 people.
Where is Angiolutions based?
Angiolutions is headquartered in De Pere, United States, in the North America region.
How does Angiolutions make money?
One revenue line is on record: medical Device Sales.
Who are Angiolutions's main competitors?
Direct peers on record are Endologix and MicroPort Scientific (Lombard Medical). Broad incumbents are Medtronic, Cook Medical, W. L. Gore & Associates, Terumo Aortic, Artivion and Abbott Vascular. Emerging players are Penumbra and Shockwave Medical.
Does Angiolutions have an API?
No public API is recorded for Angiolutions.
What industry is Angiolutions in?
Angiolutions's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 339113 and its SIC code is 3842.